Quantcast

Latest Carboplatin Stories

2010-05-20 17:00:00

INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Results of two Phase II trials evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC) will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., on June 6, 2010. The standard of care for many patients with unresectable stage...

2010-04-28 00:30:00

SEATTLE, April 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are...

2010-04-23 08:00:00

TAMPA, Fla., April 23 /PRNewswire/ -- Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer. The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy. The correlation between ERCC1 levels and therapy response was discovered at Moffitt Cancer Center and...

5bfd81e15caf4811d1285f935c36ce711
2010-04-13 07:10:25

Doctors are using a revolutionary treatment to help patients tolerate medications that they have been allergic to, according to an April 12 article by AP Medical Writer Lauran Neergaard. According to the U.S. National Institutes of Health National Library of Medicine, "Desensitization is an immunologic method that allows allergic patients to receive the sensitizing drug safely." In other words, it is a controlled method in which patients are administered a small amount of a diluted-strength...

a19202f187293888653e4e5ed00b72da1
2010-04-12 14:14:22

Ovarian cancer -- a major killer in woman -- has a new enemy, according to Austrian researchers who are hopeful a new antibody they found might step up the fight against the deadly disease. Known as AD5-10, the antibody helps weaken the resistance of cancer cells in the body's immune system, said the University of Vienna researchers whose work was published Monday. AD5-10 reduced the resistance of tumors on the protein Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL). The...

2010-03-30 06:30:00

CALGARY, March 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs (SCC lung cancer). The Principal Investigator is Dr. Alain C....

2010-03-23 07:00:00

WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018. While some...

2010-03-09 06:30:00

CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2009. "In 2009, we executed on our business plan focused on preparing the Company for late stage clinical testing and ultimately commercial launch by making substantial clinical progress, strengthening our intellectual property position and balance sheet, and scaling up...

2010-02-16 06:30:00

-- Company to Host Clinical Update Conference Call -- CALGARY, Feb. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously...

2009-12-07 19:49:39

MIT chemists have developed a new platinum compound that is as powerful as the commonly used anticancer drug cisplatin but better able to destroy tumor cells. The new compound, mitaplatin, combines cisplatin with another compound, dichloroacetate (DCA), which can alter the properties of mitochondria selectively in cancer cells. Cancer cells switch their mitochondrial properties to change the way they metabolize glucose compared to normal cells, and DCA specifically targets the altered...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related